STAT+: Revolution Medicines starts shipping experimental pancreatic cancer drug

STAT PlusBiotech Revolution Medicines starts shipping experimental pancreatic cancer drug Life-extending data for daraxonrasib create high patient demand even without FDA approval Manage alerts for this article Email this article Share this article By Adam FeuersteinMay 30, 2026 Adam Feuerstein, a senior writer and biotech columnist, is the author of Adam’s Biotech Scorecard, a subscriber-only newsletter about the crossroads of drug development, business, Wall Street, and biotechnology. Adam Feuerstein[email protected]Adam Feuerstein is a senior writer and biotech columnist, reporting on the crossroads of drug development, business, Wall Street, and biotechnology. He is also a co-host of the weekly biotech podcast The Readout Loud and author of the newsletter Adam’s Biotech Scorecard. You can reach Adam on Signal at stataf.54. CHICAGO — The biotech company Revolution Medicines has begun sending its experimental, life-extending treatment for pancreatic cancer to physicians and their patients under an early access program authorized by the Food and Drug Administration, the company’s CEO, Mark Goldsmith, told STAT. “We are now shipping the drug,” he said, speaking Friday evening at a STAT event held in conjunction with the annual meeting of the American Society of Clinical Oncology. Advertisement The drug, daraxonrasib, is not yet approved. But patients with pancreatic cancer have been clamoring for it since mid-April, when Revolution reported the striking results of a Phase 3 clinical trial. Patients treated with daraxonrasib lived nearly twice as long as patients offered standard chemotherapy — an outcome unprecedented in the pancreatic cancer field. STAT+ Exclusive Story Already have an account? Log in This article is exclusive to STAT+ subscribers Unlock this article — plus daily coverage and analysis of the biotech sector — by subscribing to STAT+. Already have an account? Log in Monthly $39 Totals $468 per year $39/month Get Started Totals $468 per year Starter $30 for 3 months, then $399/year $30 for 3 months Get Started Then $399/year Annual $399 Save 15% $399/year Get Started Save 15% 11+ Users Custom Savings start at 25%! Request A Quote Request A Quote Savings start at 25%! 2-10 Users $300 Annually per user $300/year Get Started $300 Annually per user View All Plans To read the rest of this story subscribe to STAT+. Subscribe Log In ASCO, biotech, Cancer, drug development, FDA, Pharmaceuticals, STAT+ Submit a correction requestReprints Adam Feuerstein Senior Writer, Biotech Adam Feuerstein is a senior writer and biotech columnist, reporting on the crossroads of drug development, business, Wall Street, and biotechnology. He is also a co-host of the weekly biotech podcast The Readout Loud and author of the newsletter Adam’s Biotech Scorecard. You can reach Adam on Signal at stataf.54. Newsletter Your morning rundown of the science, politics, and money driving biotech today Recommended Biotech June 1, 2026 STAT Plus: Abivax ulcerative colitis drug shows strong efficacy, but cases of cancer raise concerns Biotech June 1, 2026 STAT Plus: At ASCO, talk of barriers to cancer care, new treatments, and other big takeaways Advertisement The Readout June 1, 2026 STAT Plus: A turning point for pancreatic cancer patients Biotech June 1, 2026 STAT Plus: Servier to buy Edgewise Therapeutics’ muscular dystrophy drug Biotech May 31, 2026 STAT Plus: A standing ovation for RevMed, and caution for Akeso Subscriber Picks